The two drug giants first announced their plan to create a new venture by combining their consumer healthcare units in December 2018 with the goal of creating the world’s largest over-the-counter drug business.
The deal closed in August 2019, and the venture became the largest seller of drugstore basics such as Advil, Tums and Sensodyne toothpaste.
GlaxoSmithKline holds a 68 percent stake, and Pfizer holds 32 percent. When announcing the deal, the companies said they expect savings of about $570 million per year by 2022.
The drugmakers are now looking to focus on drug development, Bloomberg reported.
Read the full article here.
More articles on pharmacy:
Roche pulled a $1.5B fast one on US, whistleblower physician alleges
CVS adds 15 HealthHUBs to Houston area
Nationwide Children’s to build gene therapy biofactory, create more than 100 jobs
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.